Dr. Ruberg received a bachelor’s degree in mathematics from Thomas More College (1978), an MS in Statistics from Miami of Ohio (1980) and a PhD in Biostatistics from the University of Cincinnati (1984).
Dr. Ruberg was in the pharma industry for 38 years where he worked in all phases of drug development and commercialization – from R&D to Business Analytics. He retired from Lilly at the end of 2017. In his last 10 years at Lilly, he formed the Advanced Analytics Hub for which he was the Scientific Leader and ultimately the Distinguished Research Fellow. Since his retirement, he has formed his own consulting company, Analytix Thinking, which is dedicated to teaching good statistical principles and to consulting on analytical strategies for organizations.
He has published widely and lectured internationally on a variety of topics relevant to pharmaceutical research. His work and influence have touched on many important areas such as dose response, drug stability testing, Statistical Principles for Clinical Trials (ICH-E9), personalized medicine, Bayesian methods, estimands, data standards and more. He has been a Fellow of the American Statistical Association (ASA) since 1994 and was recently elected a Fellow of International Statistics Institute.
Dr. Ruberg has served in many leadership roles related to the pharmaceutical industry (e.g. PhRMA) and the statistical profession (e.g. ASA). Most notably, he served on a select Advisory Board to the Secretary of Health and Human Services in the George W. Bush Administration for creating strategies involving the development and use of electronic medical records.